A workflow integrating multi-omics with patient-specific 3D cell models for interrogating precision medicine approaches in clinically-relevant timeframes

Presented at the American Association for Cancer Research (AACR) Meeting 2026

Ali McCorkindale^1*, Elahe Minaei², Peilin Tian³, Joanna Wasielewska¹, Sean Porazinski^1†

1. Inventia Life Science, Alexandria, NSW Australia

2. Illawarra Health and Medical Research Institute, University of Wollongong, NSW Australia

3. School of Chemistry and Australian Centre of NanoMedicine, UNSW Sydney, NSW Australia

* Primary presenting author.

† Corresponding author: sean.porazinski@inventia.life

Precision oncology needs more than sequencing alone to predict which therapies will work for individual patients. This study used the RASTRUM™ Allegro platform to generate patient-specific 3D colorectal cancer tumoroid models in tunable synthetic hydrogel matrices, then combined these models with transcriptomic and proteomic profiling to support rapid, biologically relevant drug response testing.

The workflow preserved subtype-specific tumour biology, identified potential resistance mechanisms, and helped uncover alternative treatment strategies beyond standard-of-care approaches. By integrating multi-omics with scalable 3D bioprinted models, the platform provides a reproducible path to personalized therapy assessment in clinically relevant timeframes, with project initiation to preclinical testing achieved in about 8 weeks.